A Randomized, Double-Blind, Placebo-Controlled, Multiple-Dose Study to Evaluate the Pharmacokinetics, Safety and Tolerability of ABBV-553 in Healthy Volunteers and in Subjects With Psoriasis and Efficacy of ABBV-553 in Subjects With Psoriasis

Trial Profile

A Randomized, Double-Blind, Placebo-Controlled, Multiple-Dose Study to Evaluate the Pharmacokinetics, Safety and Tolerability of ABBV-553 in Healthy Volunteers and in Subjects With Psoriasis and Efficacy of ABBV-553 in Subjects With Psoriasis

Discontinued
Phase of Trial: Phase I

Latest Information Update: 09 Nov 2017

At a glance

  • Drugs ABBV 553 (Primary)
  • Indications Plaque psoriasis
  • Focus Pharmacokinetics
  • Sponsors AbbVie
  • Most Recent Events

    • 02 Nov 2017 Status changed from withdrawn prior to enrolment to discontinued.
    • 04 Sep 2017 According to an Inventiva Pharma media release, Abbvie has announced that it will cease the development of this drug.
    • 28 Aug 2017 Planned End Date changed from 21 Apr 2018 to 16 Aug 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top